(AMBS) Amarantus BioScience Holdings, Inc.
Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia.
The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") is a diagnostic blood test for Alzheimer’s disease and is being evaluated as a diagnostic blood test for Traumatic Brain injury and Chronic Traumatic Encephalopathy. (MANF) is a human growth factor that plays a key role in the prevention of apoptosis (cell death). It is being developed for the potential treatment of RP, Parkinson's disease, Wolfram syndrome, diabetes, Alzheimer's disease and traumatic brain injury.
Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").
ESS, previously known as PermaDerm® is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days.
MSPrecise is a groundbreaking advancement for the diagnosis of multiple sclerosis and is anticipated to play a pivotal role given the current high rate of misdiagnosis
MSPrecise is a lab-developed test, and the successful completion of the validation study paves the way for this clinically important test to be commercialized in 2015.
For further information, please visit www.Amarantus.com, or connect with the company in Facebook, Twitter, LinkedIn & Google+
PRESS RELEASES & NEWS ARTICLES
Amarantus Selected by People's Bank of China for Anhui SME Cross-Border Investment and Trade Cooperation Conference
NOVEMBER 13, 2015
SeeThruEquity Issues Update on Amarantus BioScience Holdings, Inc. (OTCQX: AMBS) Highlighting Partnership with U.S. Army and Orphan Drug Application for Eltoprazine
November 5, 2015
Amarantus Announces Issuance of Australian Patent No. 61/057,713 Covering Eltoprazine Treatment of Parkinson’s Disease and Alzheimer’s Disease
Oct. 29, 2015
Amarantus Appoints Curtis Scribner, MD MBA as Sr. Vice President of Regulatory Affairs
OCTOBER 26, 2015
Amarantus Submits Orphan Drug Designation Application to US FDA for Eltoprazine in the Treatment of Levodopa-Induced Dyskinesia
Oct. 22, 2015
Amarantus to Present at BIO Investor Forum 2015
Oct. 19, 2015
Past President of the American Burn Association Dr. David Ahrenholz Provides Video Interview on Potential of ESS for Treatment of Severe Burns
October 14, 2015
Bio-engineering skin to treat severe burns - Military researchers are putting the final touches on a study of a "skin substitute" grown from a patient's own cells to treat complex burns and soft tissue injuries.
October 11, 2015
Amarantus Reports Preliminary 13-Year Longitudinal Follow-Up Human Patient Data for Engineered Skin Substitute Treatment of Congenital Giant Hairy Nevus
OCTOBER 08, 2015
Amarantus Announces Publication of Study on Targeted Delivery of MANF to Brain Areas Associated With Parkinson's Disease
OCTOBER 06, 2015
Amarantus to Present at the 2015 Aegis Growth Conference
Oct. 05, 2015
Amarantus to Focus Near-Term Development Efforts on Engineered Skin Substitute for Indications in Rare Pediatric Diseases
OCTOBER 01, 2015
Amarantus Closes $5.5 Million Capital Infusion Through the Issuance of a Combination of Preferred Stock and Secured Debt Convertible
OCTOBER 01, 2015
$AMBS OTC Markets Group to Host Virtual Investor Conference for OTCQX Life Science Companies – October 1
Sept. 28, 2015
A leg up on multiple sclerosis (and Alzheimer’s)
Amarantus Receives Orphan Drug Designation From the U.S. Food and Drug Administration for MANF for the Treatment of Retinal Artery Occlusion
SEPTEMBER 14, 2015
Bio-engineering skin to treat severe burns
ESS Patients: Dr. Ahrenholz Interview Part 1
ESS vs the Competition: Dr. Ahrenholz Interview Part 2
The Need for ESS: Dr. Ahrenholz
Interview Part 3
Gerald E. Commissiong on LymPro
Published on Jul 24, 2015
Predicting Alzheimer's before it starts Published on Apr. 8, 2015
SNNLive - Amarantus BioScience
Holdings, Inc. - Dec. 12, 2014
Developing an Accurate Test for Multiple Sclerosis - Mar. 5, 2014
Amarantus BioScience Holdings, Inc.
655 Montgomery Street
San Francisco, CA 94111
c/o ICS Corporate Services SA
29 quai du Mont Blanc
email@example.com Phone: (415) 688-4484 Fax: (408) 852-4427 Gerald's email address
Gerald@amarantus.com IR Calendar
Jenene Thomas Communications
Throughout my 50+ years in the biopharmaceutical industry, I have seen many programs with great promise, but very few programs that possess the fundamentally groundbreaking scientific potential to modify disease biology inherent in MANF. This vast potential for MANF is what makes today’s announcement personally so exciting for me, as the initiation of IND-enabling studies (which start with initiation of clinical grade manufacturing) has been the rate-limiting step for true product development value creation for MANF not only for the ophthalmology programs, but also the rest of the MANF pipeline. Dr. Wen commented, "We continue to see very encouraging preclinical data with MANF. I am looking forward to continue further development of MANF in collaboration with Amarantus, as I believe it has the potential to address RP, as well as other ophthalmologic disorders with serious unmet need and improve the quality of life of patients where no viable treatments exist today."
More information “We are very pleased with the data generated in RP from Dr. Wen’s lab at University of Miami’s Bascom Palmer Eye Institute, one of the world’s most prestigious ophthalmology research and treatment centers,” said Gerald E. Commissiong, President & CEO of Amarantus BioScience Holdings, Inc. “Given the recent granting of orphan drug designations in both the US and EU, the presentation of this data is very timely as we build momentum for MANF in this devastating orphan indication, as well as continue to further establish the MANF orphan ophthalmology franchise. Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
"We are very pleased to receive orphan drug designation for MANF in RP. This represents an important milestone for the company as well as a significant step forward for our clinical and regulatory strategy," said Gerald E. Commissiong
Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.
♦ Sichenzia Ross Friedman Ference LLP, 61 Broadway, 32nd Floor, New York, NY 10006,
on Monday, December 7, 2015, at 10:30 a.m Eastern Time - Proxy Statement
♦ People's Bank of China (PBOC) and Anhui Province government to participate in the Anhui SME Cross-border Investment and
Trade Cooperation Conference (CITCC) being held on December 9-10, 2015, in Hefei City Anhui Province, China.
♦ JP Morgan Healthcare on January 11, 2016